Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07229599 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a first-in-human, open-label, multicenter Phase I/II study of MHB036C combined with MHB039A or other anti-tumor therapy in patients with advanced lung cancer. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB036C combined with MHB039A or other anti-tumor therapies.
Trial Details
NCT Number NCT07229599
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions
(from sponsor)		 Advanced Lung Cancer
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov